Drug Profile
S 910588
Latest Information Update: 15 Sep 2004
Price :
$50
*
At a glance
- Originator Aventis
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 07 Nov 2003 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)
- 07 Nov 1997 No-Development-Reported for Thrombosis in Germany (Unknown route)
- 24 Oct 1994 Preclinical development for Thrombosis in Germany (Unknown route)